ArticleScientific reports2026
Prevalence and clinical characteristics of dermatophytosis in rheumatoid arthritis according to DMARD therapy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our primary aim was to evaluate the relationship between dermatophytosis and disease-modifying antirheumatic drug (DMARD) therapy in patients with rheumatoid arthritis (RA). This prospective study was conducted in a rheumatology clinic between September 2024 and March 2025. All participants were examined for cutaneous fungal infections by a dermatologist. The study included 80 patients and 40 immunocompetent healthy controls. The most common clinical form of dermatophytosis was tinea unguium, followed by tinea pedis, in both the RA and control groups. There were no significant differences between the groups with respect to age, body mass index (BMI), or sex. Smoking was more frequent among RA patients compared with controls. Dermatophytosis was found in 56% of RA patients and 40% of controls. There was no statistically significant difference in the prevalence of dermatophytosis between RA patients and controls. Dermatophytosis was found in 55.4% of the csDMARD group and 58.3% of the b/tsDMARDs group. There was no statistically significant difference in the frequency of dermatophytosis between RA patients receiving csDMARDs and b/tsDMARDs. RA patients were also divided into two groups based on the presence of dermatophytosis. There was a statistically significant difference in the frequency of dermatophytosis according to sex between the groups. There was no statistically significant difference in the frequency of dermatophytosis with respect to DAS28, smoking status, age, BMI, cumulative methotrexate and corticosteroid exposure, and medical therapy between the groups. In our study, the most common clinical form of dermatophytosis was tinea unguium in both the RA and control groups. Although the prevalence of dermatophytosis was slightly higher in the RA population than in controls, there was no significant difference in the prevalence of dermatophytosis between the groups. Although an increased risk could not be demonstrated in the present study, further large-scale prospective studies are needed to clarify the potential relationship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.